Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : AXSM save search
Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder
Published: 2021-08-23 (Crawled : 11:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 26.13%
H: 1.63%
C: -1.63%
new drug treatment drug depression application major depressive disorder
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
Published: 2022-11-28 (Crawled : 12:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 25.02%
H: 12.17%
C: 5.22%
axs-05 disease trial therapeutics alzheimer’s
Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
Published: 2022-08-19 (Crawled : 11:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 22.3%
H: 17.77%
C: 14.76%
treatment fda approval therapeutics major depressive disorder
Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder
Published: 2021-04-26 (Crawled : 11:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 10.84%
H: 4.9%
C: 0.14%
new drug treatment fda fda acceptance drug depression major depressive disorder
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical PsychiatryAXS-05
Published: 2022-05-31 (Crawled : 17:00) - biospace.com/
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 10.36%
H: 0.0%
C: 0.0%
axs-05 trial therapeutics publication phase 3 major depressive disorder
AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders
Published: 2022-05-31 (Crawled : 18:00) - prnewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 10.36%
H: 0.0%
C: 0.0%
deadline
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry
Published: 2022-05-31 (Crawled : 12:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 10.36%
H: 0.0%
C: 0.0%
axs-05 trial therapeutics publication phase 3 major depressive disorder
AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders
Published: 2022-06-21 (Crawled : 10:00) - prnewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 8.74%
H: 0.0%
C: 0.0%
deadline
AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders
Published: 2022-07-05 (Crawled : 10:00) - prnewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 6.87%
H: 0.0%
C: 0.0%
deadline
Axsome Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
Published: 2022-03-02 (Crawled : 20:00) - biospace.com/
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 6.87%
H: 3.79%
C: 2.84%
health conference therapeutics
AXSM Investors Have Opportunity to Lead Axsome Therapeutics, Inc. Securities Fraud Lawsuit
Published: 2022-06-23 (Crawled : 05:00) - prnewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 6.2%
H: 0.0%
C: 0.0%
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
Published: 2023-05-08 (Crawled : 11:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 5.78%
H: 6.22%
C: -0.35%
update therapeutics financial results
Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry
Published: 2022-05-18 (Crawled : 12:00) - biospace.com/
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 4.9%
H: 3.4%
C: -4.3%
axs-05 trial therapeutics publication phase 2 major depressive disorder
Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Published: 2023-02-27 (Crawled : 14:00) - biospace.com/
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 4.83%
H: 3.09%
C: 0.13%
year therapeutics financial update results
Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation
Published: 2020-12-08 (Crawled : 11:02) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 4.18%
H: 0.33%
C: -1.87%
positive results positive results trial depression major depressive disorder
Axsome Therapeutics to Participate in the 1st Annual Needham Virtual Neuroscience Forum
Published: 2022-03-11 (Crawled : 12:30) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 4.1%
H: 0.0%
C: 0.0%
therapeutics annual needham
AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders
Published: 2022-06-28 (Crawled : 10:00) - prnewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 3.91%
H: 10.82%
C: 5.89%
deadline
AXSM Investors Have Opportunity to Lead Axsome Therapeutics, Inc. Securities Fraud Lawsuit
Published: 2022-06-03 (Crawled : 17:00) - prnewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 3.83%
H: 7.53%
C: 4.55%
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
Published: 2023-09-07 (Crawled : 11:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 3.77%
H: 0.55%
C: -0.45%
health congress therapeutics
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 3.64%
H: 0.35%
C: -7.48%
narcolepsy therapeutics results
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.